Veru Inc
NASDAQ:VERU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Veru Inc
Net Income (Common)
Veru Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Veru Inc
NASDAQ:VERU
|
Net Income (Common)
-$19.1m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Estee Lauder Companies Inc
NYSE:EL
|
Net Income (Common)
-$178m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bellring Brands Inc
NYSE:BRBR
|
Net Income (Common)
$183m
|
CAGR 3-Years
16%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Coty Inc
NYSE:COTY
|
Net Income (Common)
-$381.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inter Parfums Inc
NASDAQ:IPAR
|
Net Income (Common)
$168.4m
|
CAGR 3-Years
12%
|
CAGR 5-Years
35%
|
CAGR 10-Years
19%
|
|
|
elf Beauty Inc
NYSE:ELF
|
Net Income (Common)
$103.9m
|
CAGR 3-Years
30%
|
CAGR 5-Years
77%
|
CAGR 10-Years
N/A
|
|
Veru Inc
Glance View
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
See Also
What is Veru Inc's Net Income (Common)?
Net Income (Common)
-19.1m
USD
Based on the financial report for Dec 31, 2025, Veru Inc's Net Income (Common) amounts to -19.1m USD.
What is Veru Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
45%
Over the last year, the Net Income (Common) growth was 50%. The average annual Net Income (Common) growth rates for Veru Inc have been 45% over the past three years .
